A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. Issue 9 (October 2018)

• Record Type: Journal Article
• Authors: Mollica, Veronica; Di Nunno, Vincenzo; Corcioni, Beniamino; Fiorentino, Michelangelo; Nobili, Elisabetta; Schiavina, Riccardo; Golfieri, Rita; Brunocilla, Eugenio; Ardizzoni, Andrea; Massari, Francesco
• Is Part Of: Anti-cancer drugs. Volume 29:Issue 9(2018)
• Publication Date: 2018-10
• Subjects: complete response -- immune-checkpoint inhibitors -- immunotherapy -- nivolumab -- renal cell carcinoma; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000000663
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : Nivolumab is an effective and tolerable treatment for metastatic renal cell carcinoma, showing longer median overall survival than everolimus and achieving a good percentage of objective response, stable disease, and prolonged responses. However, very few cases have been reported in the literature of a complete response to nivolumab in the metastatic pretreated setting. Here, we report a case of complete response to nivolumab in II line following sunitinib in a metastatic clear cell renal cell carcinoma with favorable risk according to the IMDC criteria. This is also an interesting case on the use of immunotherapy following a long period of antiangiogenetic therapy, underlining the importance of the sequence of treatment to achieve the best possible outcome in terms of prolonged overall survival, progression-free survival, and objective response.